hn1

Anti-Human MSLN Antibody (Clone HN1) is a humanised monoclonal antibody targeting MSLN (Mesothelin), composed of the mesothelin-specific HN1, which blocks the interaction between MSLN and CA125 with cancer cells, and can be used for cancer research.

GHN105 is an orally active STING inhibitor that suppresses STING-dependent IFN-β secretion in THP-1 human monocytes with an IC50 of 4.4 μM. In mice, GHN105 reduces serum levels of IFN-β, IL-6, and CXCL10, and alleviates colitis in a DSS-induced acute colitis mouse model. Additionally, GHN105 demonstrates favorable pharmacokinetic properties in mice, with an oral bioavailability of 43% and a half-life of 1.1 hours.

HN-1, a 12-mer peptide with specificity for head and neck squamous cell carcinoma (HNSCC), penetrates tumor tissue and facilitates the translocation of agents across cell membranes [1].

Linotroban(CL-871502) is a potent selective thromboxane (TXA2) receptor antagonist with antithrombotic activity.

AHN 1-055 hydrochloride (3α-Bis-(4-fluorophenyl) Methoxytropane hydrochloride) is an inhibitor of dopamine transporter (DAT) and dopamine uptake(IC50 = 71 nM).

WHN-11, an amino-Artemisinin derivative, exhibits anticancer activity against various cancer cell lines. It depletes cellular ATP, activates autophagy, and triggers apoptosis. WHN-11 disrupts cellular protein homeostasis pathways, inducing mitochondrial fission and dysfunction. Its anticancer effects are not associated with the generation of reactive oxygen species. WHN-11 is applicable for studies on triple-negative breast cancer (TNBC).

Entinostat (MS-275) is an HDAC class I selective inhibitor of HDAC1, HDAC2 and HDAC3 (IC50=243/453/248 nM) with oral activity. Entinostat has antitumor activity.

WZ8040 is a novel mutant-selective irreversible EGFRT790M inhibitor, does not inhibit ERBB2 phosphorylation (T798I).

Verosudil, also known as AR-12286, is a potent and selective Rho kinase inhibitor. AR-12286 was well tolerated and provided statistically significant reduction in IOP (intraocular pressure) in patients with XFS (exfoliation syndrome) and OHT (ocular hypertension) or XFG (exfoliative glaucoma). This drug may represent an additional therapeutic paradigm for the treatment of XFG.

HN 11500 is an antithrombotic agent and thromboxane A2 receptor antagonist.

VMY-1-101 is a synthesized fluorescent CDK inhibitor. VMY-1-101 demonstrates potent CDK inhibitory activity, enhanced induction of G2/M arrest and modest apoptosis as compared to purvalanol B.

HN-11501 is a Thromboxane A2 receptor antagonist.